Notice: This company has been marked as potentially delisted and may not be actively trading. Novus Therapeutics (NVUS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends NVUS vs. LSB, EQ, CTXR, IBIO, CMMB, DRRX, GOVX, BOLT, BFRG, and FLGCShould you be buying Novus Therapeutics stock or one of its competitors? The main competitors of Novus Therapeutics include Lakeshore Biopharma (LSB), Equillium (EQ), Citius Pharmaceuticals (CTXR), iBio (IBIO), Chemomab Therapeutics (CMMB), DURECT (DRRX), GeoVax Labs (GOVX), Bolt Biotherapeutics (BOLT), Bullfrog AI (BFRG), and Flora Growth (FLGC). These companies are all part of the "medical" sector. Novus Therapeutics vs. Lakeshore Biopharma Equillium Citius Pharmaceuticals iBio Chemomab Therapeutics DURECT GeoVax Labs Bolt Biotherapeutics Bullfrog AI Flora Growth Novus Therapeutics (NASDAQ:NVUS) and Lakeshore Biopharma (NASDAQ:LSB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, community ranking, valuation and earnings. Does the media refer more to NVUS or LSB? In the previous week, Lakeshore Biopharma had 2 more articles in the media than Novus Therapeutics. MarketBeat recorded 2 mentions for Lakeshore Biopharma and 0 mentions for Novus Therapeutics. Novus Therapeutics' average media sentiment score of 0.00 equaled Lakeshore Biopharma'saverage media sentiment score. Company Overall Sentiment Novus Therapeutics Neutral Lakeshore Biopharma Neutral Which has more volatility and risk, NVUS or LSB? Novus Therapeutics has a beta of 2.07, suggesting that its share price is 107% more volatile than the S&P 500. Comparatively, Lakeshore Biopharma has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Which has better earnings and valuation, NVUS or LSB? Novus Therapeutics has higher earnings, but lower revenue than Lakeshore Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovus TherapeuticsN/AN/A-$16.01M-$21.58-0.20Lakeshore Biopharma$672.27M0.04-$61.09MN/AN/A Do insiders and institutionals believe in NVUS or LSB? 52.6% of Lakeshore Biopharma shares are held by institutional investors. 2.2% of Novus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is NVUS or LSB more profitable? Lakeshore Biopharma's return on equity of 0.00% beat Novus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Novus TherapeuticsN/A -133.49% -30.52% Lakeshore Biopharma N/A N/A N/A Does the MarketBeat Community believe in NVUS or LSB? Novus Therapeutics received 252 more outperform votes than Lakeshore Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformNovus TherapeuticsOutperform Votes25266.84% Underperform Votes12533.16% Lakeshore BiopharmaN/AN/A SummaryLakeshore Biopharma beats Novus Therapeutics on 5 of the 9 factors compared between the two stocks. Ad Crypto 101 MediaThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… You can get access to the report by clicking here now… Get Novus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NVUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVUS vs. The Competition Export to ExcelMetricNovus TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.26M$6.57B$5.14B$9.08BDividend YieldN/A2.99%5.09%4.23%P/E Ratio-0.1910.5990.0517.18Price / SalesN/A196.061,116.25117.05Price / CashN/A57.1643.1037.85Price / Book0.335.094.784.78Net Income-$16.01M$151.83M$120.31M$225.60M Novus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVUSNovus TherapeuticsN/A$4.36+3.3%N/A+196.6%$6.26MN/A-0.197High Trading VolumeLSBLakeshore Biopharma0.5051 of 5 stars$2.70-1.5%N/AN/A$25.14M$80.82M0.00773News CoverageGap UpEQEquillium2.7514 of 5 stars$0.70-4.4%$5.00+612.8%-7.7%$24.85M$36.08M-5.2440Gap DownCTXRCitius Pharmaceuticals1.6536 of 5 stars$3.43-2.6%$100.00+2,815.5%-86.2%$24.80MN/A-0.5820IBIOiBio0.988 of 5 stars$2.70-2.5%$4.30+59.3%N/A$24.71M$220,000.000.00100CMMBChemomab Therapeutics3.3225 of 5 stars$1.69flat$7.33+333.9%+242.9%$24.27MN/A-1.6920Positive NewsDRRXDURECT2.6264 of 5 stars$0.78-2.5%$5.00+541.9%+83.5%$24.18M$8.55M0.0080Analyst ForecastNews CoverageGOVXGeoVax Labs2.9322 of 5 stars$2.56+1.6%$14.20+454.7%-55.9%$24.16M$3.09M0.0017Analyst ForecastNews CoverageBOLTBolt Biotherapeutics2.4659 of 5 stars$0.60+3.3%$3.50+480.2%-49.8%$23.08M$7.88M0.00100BFRGBullfrog AI0.7303 of 5 stars$2.65-1.5%N/A-24.8%$23.08M$60,000.00-3.164News CoverageFLGCFlora Growth2.9322 of 5 stars$1.72+3.0%$5.00+190.7%-21.6%$23.00M$76.07M0.00280Positive NewsGap Down Related Companies and Tools Related Companies LSB Alternatives EQ Alternatives CTXR Alternatives IBIO Alternatives CMMB Alternatives DRRX Alternatives GOVX Alternatives BOLT Alternatives BFRG Alternatives FLGC Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NVUS) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
